Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (3): 195-199.DOI: 10.3969/j.issn.1673-8640.2020.03.002
Previous Articles Next Articles
WANG Junjie1, YAO Zonghui2, MA Bing2, LI Yi2, YAN Wenjuan2, WANG Shanmei2, MA Qiong2, YUAN Youhua2()
Received:
2019-08-28
Online:
2020-03-30
Published:
2020-04-17
Contact:
YUAN Youhua
CLC Number:
WANG Junjie, YAO Zonghui, MA Bing, LI Yi, YAN Wenjuan, WANG Shanmei, MA Qiong, YUAN Youhua. Risk factors and prognosis of bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae[J]. Laboratory Medicine, 2020, 35(3): 195-199.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.03.002
一般资料 | CRKP (124例) | CSKP (157例) | OR (95%CI) | P值 |
---|---|---|---|---|
男性 | 97(78.2) | 97(61.8) | 1.61(1.14~2.27) | 0.003 |
糖尿病、高血压 | 38(30.65) | 50(31.85) | 0.98(0.78~1.22) | 0.829 |
心血管系统疾病 | 32(25.81) | 14(8.92) | 2.00(1.28~3.13) | <0.001 |
呼吸系统疾病 | 59(47.58) | 22(14.01) | 2.50(1.70~3.60) | <0.001 |
神经系统疾病 | 31(25.0) | 16(10.19) | 1.80(1.20~2.70) | 0.001 |
血液系统疾病 | 24(19.35) | 27(17.20) | 0.92(0.66~1.27) | 0.618 |
消化系统疾病 | 42(33.87) | 34(21.02) | 1.30(1.02~1.76) | 0.022 |
慢性肝病 | 25(20.16) | 25(15.92) | 0.86(0.63~1.17) | 0.356 |
慢性肾病 | 25(20.16) | 8(5.09) | 2.45(1.30~4.60) | <0.001 |
肿瘤 | 12(11.22) | 35(24.11) | 1.88(1.13~3.11) | 0.005 |
感染性和过敏性疾病 | 79(63.71) | 48(30.57) | 1.67(1.47~2.39) | <0.001 |
外伤 | 11(10.20) | 4(2.13) | 1.77(1.68~2.49) | 0.019 |
骨髓穿刺、腰椎穿刺 | 42(33.87) | 30(19.11) | 1.46(1.10~1.96) | 0.005 |
其他穿刺 | 59(47.58) | 37(23.57) | 1.68(1.30~2.20) | <0.001 |
器官移植、干细胞移植 | 3(2.42) | 6(3.82) | 1.34(0.53~3.40) | 0.748 |
化疗 | 23(18.55) | 33(21.02) | 1.09(0.77~1.50) | 0.610 |
近3个月接受外科手术 | 90(72.58) | 45(28.66) | 6.90(3.70~9.90) | <0.001 |
中心静脉导管 | 60(48.39) | 28(17.83) | 2.10(1.50~2.90) | <0.001 |
血液透析、血浆置换 | 26(20.97) | 10(6.37) | 4.20(1.90~9.80) | <0.001 |
导尿管 | 79(63.71) | 29(18.47) | 2.80(2.00~3.80) | <0.001 |
气管插管 | 81(65.32) | 34(21.66) | 2.50(1.90~3.40) | <0.001 |
胃管 | 78(62.90) | 34(21.66) | 2.40(1.80~3.20) | <0.001 |
曾入住ICU | 99(79.84) | 49(31.21) | 3.60(2.50~5.50) | <0.001 |
转院 | 85(68.55) | 58(36.94) | 1.80(1.40~2.20) | <0.001 |
转科 | 79(63.71) | 38(24.20) | 2.20(1.70~2.90) | <0.001 |
反复输血 | 88(70.97) | 61(38.85) | 2.20(1.60~3.00) | <0.001 |
一般资料 | CRKP (124例) | CSKP (157例) | OR (95%CI) | P值 |
---|---|---|---|---|
男性 | 97(78.2) | 97(61.8) | 1.61(1.14~2.27) | 0.003 |
糖尿病、高血压 | 38(30.65) | 50(31.85) | 0.98(0.78~1.22) | 0.829 |
心血管系统疾病 | 32(25.81) | 14(8.92) | 2.00(1.28~3.13) | <0.001 |
呼吸系统疾病 | 59(47.58) | 22(14.01) | 2.50(1.70~3.60) | <0.001 |
神经系统疾病 | 31(25.0) | 16(10.19) | 1.80(1.20~2.70) | 0.001 |
血液系统疾病 | 24(19.35) | 27(17.20) | 0.92(0.66~1.27) | 0.618 |
消化系统疾病 | 42(33.87) | 34(21.02) | 1.30(1.02~1.76) | 0.022 |
慢性肝病 | 25(20.16) | 25(15.92) | 0.86(0.63~1.17) | 0.356 |
慢性肾病 | 25(20.16) | 8(5.09) | 2.45(1.30~4.60) | <0.001 |
肿瘤 | 12(11.22) | 35(24.11) | 1.88(1.13~3.11) | 0.005 |
感染性和过敏性疾病 | 79(63.71) | 48(30.57) | 1.67(1.47~2.39) | <0.001 |
外伤 | 11(10.20) | 4(2.13) | 1.77(1.68~2.49) | 0.019 |
骨髓穿刺、腰椎穿刺 | 42(33.87) | 30(19.11) | 1.46(1.10~1.96) | 0.005 |
其他穿刺 | 59(47.58) | 37(23.57) | 1.68(1.30~2.20) | <0.001 |
器官移植、干细胞移植 | 3(2.42) | 6(3.82) | 1.34(0.53~3.40) | 0.748 |
化疗 | 23(18.55) | 33(21.02) | 1.09(0.77~1.50) | 0.610 |
近3个月接受外科手术 | 90(72.58) | 45(28.66) | 6.90(3.70~9.90) | <0.001 |
中心静脉导管 | 60(48.39) | 28(17.83) | 2.10(1.50~2.90) | <0.001 |
血液透析、血浆置换 | 26(20.97) | 10(6.37) | 4.20(1.90~9.80) | <0.001 |
导尿管 | 79(63.71) | 29(18.47) | 2.80(2.00~3.80) | <0.001 |
气管插管 | 81(65.32) | 34(21.66) | 2.50(1.90~3.40) | <0.001 |
胃管 | 78(62.90) | 34(21.66) | 2.40(1.80~3.20) | <0.001 |
曾入住ICU | 99(79.84) | 49(31.21) | 3.60(2.50~5.50) | <0.001 |
转院 | 85(68.55) | 58(36.94) | 1.80(1.40~2.20) | <0.001 |
转科 | 79(63.71) | 38(24.20) | 2.20(1.70~2.90) | <0.001 |
反复输血 | 88(70.97) | 61(38.85) | 2.20(1.60~3.00) | <0.001 |
一般资料 | 治疗成功(137例) | 治疗失败(144例) | OR(95%CI) | P值 |
---|---|---|---|---|
男性 | 88 | 106 | 0.64(0.39~1.10) | 0.089 |
糖尿病、高血压 | 42 | 46 | 1.10(0.64~1.76) | 0.816 |
心血管系统疾病 | 14 | 32 | 2.51(1.27~4.95) | 0.007 |
呼吸系统疾病 | 21 | 60 | 3.95(2.23~6.98) | <0.001 |
神经系统疾病 | 12 | 35 | 3.35(1.65~6.76) | <0.001 |
血液系统疾病 | 22 | 29 | 1.32(0.72~2.43) | 0.375 |
消化系统疾病 | 39 | 37 | 0.87(0.51~1.47) | 0.601 |
慢性肝病 | 22 | 28 | 1.26(0.68~2.33) | 0.460 |
慢性肾病 | 9 | 24 | 2.84(1.27~6.40) | 0.009 |
肿瘤 | 25 | 22 | 0.81(0.43~1.50) | 0.505 |
感染性和过敏性疾病 | 46 | 81 | 2.54(1.57~4.13) | <0.001 |
外伤 | 4 | 11 | 2.75(0.85~8.86) | 0.079 |
骨髓穿刺、腰椎穿刺 | 23 | 49 | 2.56(1.50~4.50) | 0.001 |
其他穿刺 | 36 | 60 | 2.00(1.20~3.30) | 0.007 |
器官移植、干细胞移植 | 7 | 2 | 0.26(0.05~1.30) | 0.096 |
化疗 | 27 | 29 | 0.99(0.74~1.30) | 0.928 |
近3个月接受外科手术 | 44 | 91 | 3.63(2.20~5.90) | <0.001 |
中心静脉导管 | 16 | 72 | 7.60(4.10~13.90) | <0.001 |
血液透析、血浆置换 | 7 | 29 | 4.68(1.98~11.10) | <0.001 |
气管插管 | 18 | 97 | 13.60(7.40~25.00) | <0.001 |
导尿管 | 25 | 83 | 6.10(3.50~10.50) | <0.001 |
胃管 | 29 | 83 | 5.10(2.90~8.60) | <0.001 |
曾入住ICU | 96 | 37 | 7.90(4.40~11.10) | <0.001 |
转院 | 47 | 96 | 3.80(2.30~6.30) | <0.001 |
转科 | 38 | 79 | 3.19(1.90~5.20) | <0.001 |
反复输血 | 56 | 93 | 2.81(1.56~4.60) | <0.001 |
CSKP | 108 | 49 | 0.14(0.08~0.24) | <0.001 |
CRKP | 29 | 95 | 7.10(4.80~20.00) | <0.001 |
一般资料 | 治疗成功(137例) | 治疗失败(144例) | OR(95%CI) | P值 |
---|---|---|---|---|
男性 | 88 | 106 | 0.64(0.39~1.10) | 0.089 |
糖尿病、高血压 | 42 | 46 | 1.10(0.64~1.76) | 0.816 |
心血管系统疾病 | 14 | 32 | 2.51(1.27~4.95) | 0.007 |
呼吸系统疾病 | 21 | 60 | 3.95(2.23~6.98) | <0.001 |
神经系统疾病 | 12 | 35 | 3.35(1.65~6.76) | <0.001 |
血液系统疾病 | 22 | 29 | 1.32(0.72~2.43) | 0.375 |
消化系统疾病 | 39 | 37 | 0.87(0.51~1.47) | 0.601 |
慢性肝病 | 22 | 28 | 1.26(0.68~2.33) | 0.460 |
慢性肾病 | 9 | 24 | 2.84(1.27~6.40) | 0.009 |
肿瘤 | 25 | 22 | 0.81(0.43~1.50) | 0.505 |
感染性和过敏性疾病 | 46 | 81 | 2.54(1.57~4.13) | <0.001 |
外伤 | 4 | 11 | 2.75(0.85~8.86) | 0.079 |
骨髓穿刺、腰椎穿刺 | 23 | 49 | 2.56(1.50~4.50) | 0.001 |
其他穿刺 | 36 | 60 | 2.00(1.20~3.30) | 0.007 |
器官移植、干细胞移植 | 7 | 2 | 0.26(0.05~1.30) | 0.096 |
化疗 | 27 | 29 | 0.99(0.74~1.30) | 0.928 |
近3个月接受外科手术 | 44 | 91 | 3.63(2.20~5.90) | <0.001 |
中心静脉导管 | 16 | 72 | 7.60(4.10~13.90) | <0.001 |
血液透析、血浆置换 | 7 | 29 | 4.68(1.98~11.10) | <0.001 |
气管插管 | 18 | 97 | 13.60(7.40~25.00) | <0.001 |
导尿管 | 25 | 83 | 6.10(3.50~10.50) | <0.001 |
胃管 | 29 | 83 | 5.10(2.90~8.60) | <0.001 |
曾入住ICU | 96 | 37 | 7.90(4.40~11.10) | <0.001 |
转院 | 47 | 96 | 3.80(2.30~6.30) | <0.001 |
转科 | 38 | 79 | 3.19(1.90~5.20) | <0.001 |
反复输血 | 56 | 93 | 2.81(1.56~4.60) | <0.001 |
CSKP | 108 | 49 | 0.14(0.08~0.24) | <0.001 |
CRKP | 29 | 95 | 7.10(4.80~20.00) | <0.001 |
抗菌药物 | 治疗成功(137例) | 治疗失败(144例) | OR(95%CI) | P值 |
---|---|---|---|---|
青霉素 | 13 | 15 | 0.98(0.51~2.40) | 0.795 |
头孢类 | 21 | 32 | 1.58(0.86~2.90) | 0.14 |
碳青霉烯类 | 46 | 98 | 4.22(2.56~6.94) | <0.001 |
氨曲南 | 9 | 2 | 0.18(0.04~0.94) | 0.025 |
酶抑制剂 | 17 | 61 | 5.19(2.83~9.50) | <0.001 |
氨基糖苷类 | 14 | 12 | 0.80(0.36~1.79) | 0.586 |
喹诺酮类 | 19 | 20 | 1.02(0.51~1.97) | 0.996 |
磺胺类 | 6 | 2 | 0.31(0.06~1.60) | 0.251 |
厌氧类 | 6 | 8 | 1.28(0.43~3.80) | 0.661 |
利奈唑胺 | 6 | 21 | 3.73(1.50~9.50) | 0.004 |
抗真菌药 | 9 | 26 | 3.13(1.40~6.96) | 0.004 |
替考拉宁 | 8 | 19 | 2.45(1.04~5.80) | 0.037 |
万古霉素 | 1 | 10 | 10.15(1.28~80.4) | 0.007 |
抗菌药物 | 治疗成功(137例) | 治疗失败(144例) | OR(95%CI) | P值 |
---|---|---|---|---|
青霉素 | 13 | 15 | 0.98(0.51~2.40) | 0.795 |
头孢类 | 21 | 32 | 1.58(0.86~2.90) | 0.14 |
碳青霉烯类 | 46 | 98 | 4.22(2.56~6.94) | <0.001 |
氨曲南 | 9 | 2 | 0.18(0.04~0.94) | 0.025 |
酶抑制剂 | 17 | 61 | 5.19(2.83~9.50) | <0.001 |
氨基糖苷类 | 14 | 12 | 0.80(0.36~1.79) | 0.586 |
喹诺酮类 | 19 | 20 | 1.02(0.51~1.97) | 0.996 |
磺胺类 | 6 | 2 | 0.31(0.06~1.60) | 0.251 |
厌氧类 | 6 | 8 | 1.28(0.43~3.80) | 0.661 |
利奈唑胺 | 6 | 21 | 3.73(1.50~9.50) | 0.004 |
抗真菌药 | 9 | 26 | 3.13(1.40~6.96) | 0.004 |
替考拉宁 | 8 | 19 | 2.45(1.04~5.80) | 0.037 |
万古霉素 | 1 | 10 | 10.15(1.28~80.4) | 0.007 |
[1] | AMIT S,MISHALI H,KOTLOVSKY T,et al.Bloodstream infections among carriers of carbapenem-resistant Klebsiella pneumoniae:etiology,incidence and predictors[J]. Clin Microbiol Infect,2015,21(1):30-34. |
[2] | XU L,SUN X,MA X.Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae[J]. Ann Clin Microbiol Antimicrob,2017,16(1):18. |
[3] | ZHENG X,WANG J F,XU W L,et al.Clinical and molecular characteristics,risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in the intensive care unit[J]. Antimicrob Resist Infect Control,2017,6:102. |
[4] | HSU J F,CHU S M,HUANG Y C,et al. Predictors of clinical and microbiological treatment failure in neonatal bloodstream infections[J]. Clin Microbiol Infect,2015,21(5):482.e9-482.e4.82E17. |
[5] | KIDDEE A,ASSAWATHEPTAWEE K,NA-UDOM A,et al.Risk factors for gastrointestinal colonization and acquisition of carbapenem-resistant Gram-negative bacteria among patients in intensive care units in Thailand[J]. Antimicrob Agents Chemother,2018,62(8):e00341-18. |
[6] | KOHLER P P,VOLLING C,GREEN K,et al.Carbapenem resistance,initial antibiotic therapy,and mortality in Klebsiella pneumoniae bacteremia:a systematic review and meta-analysis[J]. Infect Control Hosp Epidemiol,2017,38(11):1319-1328. |
[7] | ZHANG Y,GUO L Y,SONG W Q,et al.Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients[J]. BMC Infect Dis,2018,18(1):248. |
[8] | RIGHI E,PERI A M,HARRIS P N,et al.Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use:systematic review and meta-analysis[J]. J Antimicrob Chemother,2017,72(3):668-677. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||